目的 探討明目地黃丸聯(lián)合復方樟柳堿治療視神經(jīng)萎縮的臨床療效。方法 選擇2014年6月—2015年6月西安市中醫(yī)醫(yī)院眼科收治的視神經(jīng)萎縮患者88例,按照治療方案不同分為對照組和治療組,每組各44例。對照組顳淺動脈旁皮下注射復方樟柳堿注射液,2 mL/次,1次/d。治療組在對照組治療方法上口服明目地黃丸,1丸/次,2次/d。兩周為1個療程,兩組患者均連續(xù)治療3個療程,每個療程間隔5 d。觀察兩組患者的臨床療效,同時比較兩組視野缺損、P₁₀₀波潛伏期、視力提高行數(shù)的變化。結果 治療后,對照組和治療組總有效率分別為75.00%、90.91%,兩組比較差異有統(tǒng)計學意義(P<0.05)。治療后,兩組患者視野缺損、P₁₀₀波潛伏期均顯著降低,同組治療前后差異具有統(tǒng)計學意義(P<0.05);且治療組的改善程度優(yōu)于對照組,兩組比較差異具有統(tǒng)計學意義(P<0.05)。治療組視力提高行數(shù)優(yōu)于對照組,兩組比較差異具有統(tǒng)計學意義(P<0.05)。對照組和治療組不良反應發(fā)生率分別為2.27%、4.55%,兩組比較差異無統(tǒng)計學意義。結論 明目地黃丸聯(lián)合復方樟柳堿治療視神經(jīng)萎縮的臨床療效顯著,可促進患者視力恢復,減小視野缺損,具有一定的臨床推廣應用價值。

Objective To observe the clinical effect of Mingmu Dihuang Pills combined with compound anisodine in treatment of optic atrophy. Methods Patients (88 cases) with optic atrophy in Department of Ophthalmology of Xi'an Hospital of Traditional Chinese Medicine from June 2014 to June 2015 were enrolled in this study. According to the different treatment plan, patients were divided into treatment group (44 cases) and control group (44 cases). The patients in the control group were sc administered with Compound Anisodine Hydrobromide Injection, 2 mL/time, once daily. The patients in the treatment group were po administered with Mingmu Dihuang Pills on the basis of control group, 1 pill/time, twice daily. Two weeks was as one course, and the patients in two groups were treated for three courses. Each course had a five-day interval. After treatment, the clinical efficacy were evaluated, and the changes of visual field defect, P₁₀₀ wave incubation period, the lines number of eyesight improve in two groups were compared. Results After treatment, the clinical efficacies in the control and treatment groups were 75.00% and 90.91%, respectively, and there were differences between two groups (P < 0.05). After treatment, visual field defect and P₁₀₀ wave incubation period in two groups were significantly decreased, and the difference was statistically significant in the same group (P < 0.05). After treatment, the observational indexes in the treatment group were significantly better than those in the control group, with significant difference between two groups (P < 0.05). The line numbers of eyesight improve in treatment group was better than that of control group, with significant difference between two groups (P < 0.05). The incidence of adverse reactions in the control and treatment groups were 2.27% and 4.55%, respectively, and there were no differences between two groups. Conclusion Mingmu Dihuang Pills combined with compound anisodine has distinct clinical effect in treatment of optic atrophy, and can promote the patients' visual acuity, also can reduce visual field defect, which has a certain clinical application value.